Amgen says Lumakras cuts risk of lung cancer progression by 34%

Amgen Inc. most cancers drug, Lumakras, is displayed in its packaging at Thousand Oaks, in California, United States September 10, 2022. Amgen/Handout by way of REUTERS

Sept 11 (Reuters) – Amgen Inc’s (AMGN.O) Lumakras tablet decreased the chance of illness development in sufferers with superior lung most cancers by 34% in contrast with chemotherapy in a scientific trial, the corporate mentioned on Sunday.

There was no vital distinction in general survival between the 2 remedies within the confirmatory examine required by U.S. regulators as a situation of accelerated approval for Lumakras. However Amgen mentioned the trial was not designed to detect a survival distinction.

The corporate can also be testing whether or not the drug may very well be efficient in opposition to lung most cancers earlier within the illness, and mentioned final month a small examine of Lumakras mixed with immunotherapy discovered excessive charges of liver toxicity and that additional examine was wanted.

Extra detailed outcomes from the 345-patient examine, together with median progression-free survival – the size of time till the most cancers begins to worsen – can be offered on Monday on the annual assembly of the European Society for Medical Oncology (ESMO) in Paris.

Wall Avenue analysts, reminiscent of Michael Yee at Jefferies, have mentioned traders anticipate a modest good thing about round two months for the Amgen drug over chemotherapy.

Amgen mentioned 33% of Lumakras trial sufferers skilled severe negative effects reminiscent of diarrhea and elevated liver enzymes, in contrast with 40% of chemotherapy sufferers.

The medicine is designed to focus on a mutated type of a gene often known as KRAS that happens in about 13% of non-small cell lung cancers, the most typical type of the illness, and fewer regularly in another stable tumors.

“We’re providing the selection of a tablet … versus chemotherapy meaning going to the hospital,” Amgen oncology head Jean-Charles Soria instructed Reuters.

Lumakras was authorised by the U.S. Meals and Drug Administration final yr below an accelerated pathway for superior lung most cancers sufferers with KRAS mutations whose illness has worsened after remedy with chemotherapy or different medicines.

The company additionally requested Amgen to review a decrease dose of Lumakras, recognized chemically as sotorasib. The corporate mentioned these outcomes are anticipated within the fourth quarter of this yr.

The FDA is slated to make an approval determination on a possible rival KRAS-targeting drug, Mirati Therapeutics Inc’s (MRTX.O) adagrasib, by mid-December.

Mirati in Might mentioned adagrasib shrank tumors in 44% of superior lung most cancers sufferers in scientific trials, but in addition brought about severe negative effects in 43% of them.

On the ESMO assembly this week, Amgen can also be presenting early knowledge from a trial of Lumakras together with different most cancers medication for sufferers with colorectal most cancers.

Reporting By Deena Beasley
Modifying by Invoice Berkrot

: .